New pill tested to tame uncontrollable hives

NCT ID NCT07219615

Summary

This study is testing an oral medication called ritlecitinib to see if it can safely reduce itchy hives and swelling in adults with chronic spontaneous urticaria (CSU) that isn't controlled by standard allergy medicines. About 200 participants will be randomly assigned to take either a 50mg dose, a 100mg dose, or a placebo pill daily for 12 weeks, followed by a 12-week extension period. The main goal is to measure changes in hive and itch activity and monitor for any side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Allergy, Asthma and Clinical Research

    NOT_YET_RECRUITING

    Oklahoma City, Oklahoma, 73120, United States

  • Revival Research Institute, LLC

    RECRUITING

    Troy, Michigan, 48084, United States

Conditions

Explore the condition pages connected to this study.